Precision AQ

Precision AQ is a commercialization partner to the biopharma industry, working with pharmaceutical and biotech clients on product commercialization across the whole lifecycle, from early pipeline through launch to post-launch optimisation. The firm, which operates under the Precision Medicine Group umbrella and was reintroduced under its current name in May 2024 following its earlier life as Precision Value & Health, employs more than 1,200 experts worldwide. Its staff include former access decision-makers, clinicians, scientists, strategists and communications professionals.

For technical leaders, the central proposition is data. Precision AQ's Data Solutions practice integrates technology and expertise to reconcile disparate data sources and make access to medicines actionable. This sits alongside technology-enabled commercialisation and market access analytics, which are delivered through a set of service lines: Value and Access, Medical Communications, Investor Relations, and Brand Strategy and Marketing. Together these cover market access and value strategy, medical communications, investor relations for life sciences clients, and brand strategy and marketing across the product lifecycle.

The company reports having supported launches and label expansions for a significant share of FDA-approved drugs. Its clients span the pharmaceutical, biotechnology, biopharma, healthcare and life sciences sectors, and its operations are global. The firm describes its approach as combining data with human insight, framing the mix as where IQ meets EQ.